Risperidone versus placebo for schizophrenia

Keyphrases

• 19th Century 10%
• Adverse Effects 10%
• Adverse Events 10%
• Allocation Concealment 10%
• AMED 10%
• Antipsychotics 10%
• Assessment Development 10%
• Attrition 10%
• Attrition Rate 10%
• Between-group 10%
• CINAHL 10%
• Clinical Costs 10%
• Clinical Effect 10%
• Clinical Global Impression Scale 20%
• Clinical Improvement 10%
• Clinical Response 10%
• Clinical Safety 10%
• Clinical Trials 10%
• Clinically Meaningful Improvement 10%
• Clinically Significant 10%
• Clozapine 10%
• Cochrane 10%
• Confidence Interval 100%
• Continuous Data 10%
• Cost-effectiveness 10%
• Data Reporting 10%
• Dichotomous Data 10%
• Directional Effects 10%
• Embase 10%
• Evaluation Assessment 10%
• Extracted Data 10%
• Extrapyramidal Side Effects 10%
• Extrapyramidal Symptoms 10%
• Generic Forms 10%
• Grading of Recommendations 10%
• Group 12 10%
• Industry Sponsorship 10%
• Intention-to-treat 10%
• MEDLINE 10%
• Mental States 20%
• Missing Data 10%
• No Significant Difference 10%
• PANSS 10%
• People with Schizophrenia 10%
• Pharmaceutical Companies 10%
• Placebo 100%
• Placebo Groups 10%
• Placebo Treatment 10%
• PsycINFO 10%
• PubMed 10%
• Randomized Clinical Trial 90%
• Review Authors 10%
• Risk Areas 10%
• Risk of Bias 10%
• Risk Ratio 90%
• Risperidone 100%
• Safety Effectiveness 10%
• Schizophrenia 100%
• Schizophrenia Spectrum Disorders 10%
• Search Methods 10%
• Second-generation Antipsychotics 10%
• Selection Bias 10%
• Selection Criteria 10%
• Selective Reporting 10%
• Sensitivity Analysis 10%
• Summary of Findings Table 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Antipsychotic 10%
• Clinical Trial 10%
• Clozapine 10%
• Extrapyramidal Symptoms 10%
• Group Trial 10%
• Placebo 100%
• Randomized Clinical Trial 90%
• Risperidone 100%
• Typical Antipsychotic 10%